Theravance Biopharma
TBPH
107 hedge funds and large institutions have $946M invested in Theravance Biopharma in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 32 reducing their positions, and 26 closing their positions.
6,800% more call options, than puts
Call options by funds: $69K | Put options by funds: $1K
22% more capital invested
Capital invested by funds: $775M → $946M (+$170M)
3% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 32
0.62% more ownership
Funds ownership: 82.6% → 83.21% (+0.62%)
9% less funds holding
Funds holding: 118 → 107 (-11)
42% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$14.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.3M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$11.2M |
| 4 |
Morgan Stanley
New York
|
+$8.39M |
| 5 |
BlackRock
New York
|
+$3.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.3M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$8.14M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$6.32M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.62M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FCA
126
FinTrust Capital Advisors
Greenville,
South Carolina
| – | -$3 | -200 | Closed |
|
|
MAM
127
Meeder Asset Management
Dublin,
Ohio
| – | -$2K | -172 | Closed |
|
|
GT
128
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$1K | -73 | Closed |
|
129
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -54 | Closed |
|
|
EI
130
Ellevest Inc
New York
| – | +$162 | +9 | New |
|
131
Simplex Trading
Chicago,
Illinois
| – | +$269 | +15 | New |
|
TBPH Hedge Fund Activity: Q4 2020 in Review
107 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2020, worth a combined $946M — up 22% from $775M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of TBPH and 15 opened new positions — a net loss of 11 holders — while 32 trimmed existing stakes and 33 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $14.8M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10.3M sold.
- 107 institutional investors held Theravance Biopharma (TBPH) as of Q4 2020, down from 118 in Q3 2020.
- Funds reported $946M of Theravance Biopharma stock for Q4 2020, up 22% quarter-over-quarter.
- 15 funds opened new Theravance Biopharma positions in Q4 2020 and 26 closed out, a net change of -11 holders.
- The largest Theravance Biopharma buyer in Q4 2020 was Great Point Partners, an estimated $14.8M added.
- The largest Theravance Biopharma seller in Q4 2020 was Adage Capital Partners, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2020.